Targeting the MYCN interaction network in neuroblastoma.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Neuroblastoma is a leading cause of childhood cancer mortality, with high-risk forms having poor survival rates.
• MYCN oncogene amplification is a critical factor in high-risk neuroblastoma, driving tumor progression.
• The MYCN protein, a transcription factor, is considered 'undruggable' due to its structure.

Purpose of the Study:

• To explore the MYCN molecular interactome as a novel therapeutic target.
• To review strategies for disrupting MYCN interactions and promoting its degradation.

Main Methods:

• Review of existing literature on MYCN biology and its interaction partners.
• Analysis of functional and structural features of MYCN-protein interactions.
• Exploration of emerging therapeutic strategies, including PROTACs.

Main Results:

• Identified key MYCN interaction partners including MAX, WDR5, TFIIIC5, and Aurora kinase A.
• Highlighted the potential of targeting MYCN's interactome for therapeutic intervention.
• Discussed protein degradation pathways as a means to target MYCN.

Conclusions:

• Disrupting MYCN interactions and promoting its degradation offers promising therapeutic avenues for MYCN-driven neuroblastoma.
• Integrating MYCN biology, structural data, and chemical biology can lead to effective targeted therapies.
• These approaches hold potential for improving survival rates in high-risk neuroblastoma patients.